KBKatrina A. Bicknell

Katrina A. Bicknell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Katrina A. Bicknell has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids

    by Stephen Swioklo, Kimberly A. Watson, Elizabeth M. Williamson, Jonathan A. Farrimond, Sophie E. Putnam, Katrina A. Bicknell

    Epidemiological studies suggest that fruits and vegetables may play a role in promoting bone growth and preventing age-related bone loss, attributable, at least in part, to phytochemicals such as flavonoids stimulating osteoblastogenesis. Through systematically screening the effect of flavonoids on the osteogenic differentiation of human mesenchymal stem cells in vitro and correlating activity with chemical structure using comparative molecular field analysis, we have successfully identified important structural features that relate to their activity, as well as reliably predicted the activity of compounds with unknown activity. Contour maps emphasized the importance of electronegativity, steric bulk, and a 2-C–3-C double bond at the flavonoid C-ring, as well as overall electropositivity and reduced steric bulk at the flavonoid B-ring. These results support a role for certain flavonoids in promoting osteogenic differentiation, thus their potential for preventing skeletal deterioration, as well as providin...


  • TROGLITAZONE INHIBITS VASCULAR SMOOTH MUSCLE CELL PROLIFERATION IN A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA (PPARÎł)-INDEPENDENT MANNER

    by Hossam Alkoot, Adam Hargreaves, Abeer Dannoura, Ines Pereira, Alejandro Giraldo-Ramirez, Gavin Brooks, Katrina Bicknell

    Re-occlusion of blood vessels following percutaneous coronary intervention with stenting (in stent stenosis) occurs in 5–10% of patients receiving drug-eluting stents. Re-occlusion of the treated vessel is observed when vascular smooth muscle cells (VSMCs) proliferate and migrate in response to vessel injury, inflammation and impaired healing of the endothelial cell layer. Novel drug eluting stents that reduce inflammation and permit endothelial repair whilst preventing detrimental VSMC proliferation and migration might reduce the occurrence of in stent restenosis. We previously have shown that ibuprofen has differential effects on vascular smooth muscle and endothelial cell proliferation and migration and, thus, might be a promising drug to deliver in a novel drug eluting stent platform. We do not fully understand why vascular smooth muscle and endothelial cells respond differently to ibuprofen but hypothesise that ibuprofen is regulating VSM C proliferation and migration, at least in part, via a peroxisome proliferator-activated receptor gamma (PPARγ)-dependent mechanism. In this study, we have used PPARγ agonists, troglitazone, pioglitazone, and rosiglitazone, to establish the role of PPARγ in the regulation of cell proliferation in the A10 VSMC cell line. Interestingly, whilst 50 µM and 100 µM troglitazone inhibited A10 VSMC proliferation by 58.9±4.6% and 21.6±4.8%, respectively, pioglitazone and rosiglitazone had no effect on VSMC cell proliferation at any concentrations tested. The observations that only one PPARγ agonist tested inhibited VSMC proliferation and that high concentrations of troglitazone were required to observe a significant effect (EC50=54.6 µM) suggest that troglitazone might be acting in a PPARγ-independent manner.

  • Ibuprofen inhibits migration and proliferation of human coronary artery smooth muscle cells by inducing a differentiated phenotype: role of peroxisome proliferator-activated receptor Îł

    by Abeer Dannoura, Alejandro Giraldo, Ines Pereira, Jonathan M. Gibbins, Phil R. Dash, Katrina A Bicknell, Gavin Brooks

    Objectives: The search for agents that are capable of preventing restenosis and reduce the risk of late thrombosis is of utmost importance. In this study we aim to evaluate the in vitro effects of ibuprofen on proliferation and migration of human coronary artery smooth muscle cells and on endothelial cells. Methods: Cell proliferation was evaluated by trypan blue exclusion. Cell migration was assessed by wound-healing ‘scratch’ assay and time-lapse video microscopy. Protein expression was assessed by immunoblotting, and morphology by immunocytochemistry. The involvement of the PPARγ pathway was studied with the agonist troglitazone, and the use of selective antagonists such as PGF2α and GW9662. Key findings: We demonstrate that ibuprofen inhibits proliferation and migration of HCASMCs and induces a switch in HCASMCs towards a differentiated and contractile phenotype, and that these effects are mediated through the PPARγ pathway. Importantly we also show that the effects of ibuprofen are cell type-specific as it does not affect migration and proliferation of endothelial cells. Conclusions: Taken together, our results suggest that ibuprofen could be an effective drug for the development of novel drug-eluting stents that could lead to reduced rates of restenosis and potentially other complications of DES implantation.


  • A Comparison of Thiolated and Disulfide-Crosslinked Polyethylenimine for Nonviral Gene Delivery

    by Latha Aravindan, Katrina A. Bicknell, Gavin Brooks, Vitaliy V. Khutoryanskiy, Adrian C. Williams

    Branched polyethylenimine (25 kDa) is thiolated and compared with redox‐sensitive crosslinked derivatives. Both polymers thiol contents are assessed; the thiolated polymers have 390–2300 mmol SH groups/mol, whereas the crosslinked polymers have lower thiol contents. Cytotoxicity assays show that both modified polymers give lower hemolysis than unmodified PEI. Increased thiol content increases gene transfer efficiency but also elevates cytotoxicity. Crosslinking improves plasmid DNA condensation and enhances transfection efficiency, but extensive crosslinking overstabilizes the polyplexes and decreases transfection, emphasizing the need to balance polyplex stabilization and unpacking. Thus, at low levels of crosslinking, 25 kDa PEI can be an efficient redox‐sensitive carrier system.


  • Limitations of the MRL mouse as a model for cardiac regeneration

    by Fleur L. Moseley, Matthew E Faircloth, Wendy Lockwood, Michael S. Marber, Katrina A Bicknell, Petr Valasek, Gavin Brooks

    Objective: Myocardial repair following injury in mammals is restricted such that damaged areas are replaced by scar tissue, impairing cardiac function. MRL mice exhibit exceptional regenerative healing in an ear punch wound model. Some myocardial repair with restoration of heart function has also been reported following cryoinjury. Increased cardiomyocyte proliferation and a foetal liver stem cell population were implicated. We investigated molecular mechanisms facilitating myocardial repair in MRL mice to identify potential therapeutic targets in non-regenerative species. Methods: Expressions of specific cell-cycle regulators that might account for regeneration (CDKs 1, 2, 4 and 6; cyclins A, E, D1 and B1; p21, p27 and E2F5) were compared by immunoblotting in MRL and control C57BL/6 ventricles during development. Flow cytometry was used to investigate stem cell populations in livers from foetal mice, and infarct sizes were compared in coronary artery-ligated and sham-treated MRL and C57BL/6 adult mice. Key findings: No differences in the expressions of cell cycle regulators were observed between the two strains. Expressions of CD34+Sca1+ckit-, CD34+Sca1+ckit+ and CD34+Sca1-ckit+ increased in livers from C57BL/6 vs MRL mice. No differences were observed in infarct sizes, levels of fibrosis, Ki67 staining or cardiac function between MRL and C57BL/6 mice. Conclusions: No intrinsic differences were observed in cell cycle control molecules or stem cell populations between MRL and control C57BL mouse hearts. Pathophysiologically relevant ischaemic injury is not repaired more efficiently in MRL myocardium, questioning the use of the MRL mouse as a reliable model for cardiac regeneration in response to pathophysiologically relevant forms of injury.


  • Open Access

    Over Expression of Plk1 Does Not Induce Cell Division in Rat Cardiac Myocytes In Vitro

    by Carmen H. Coxon, Katrina A. Bicknell, Fleur L. Moseley, Gavin Brooks

    Mammalian cardiac myocytes withdraw from the cell cycle during post-natal development, resulting in a non-proliferating, fully differentiated adult phenotype that is unable to repair damage to the myocardium, such as occurs following a myocardial infarction. We and others previously have shown that forced expression of certain cell cycle molecules in adult cardiac myocytes can promote cell cycle progression and division in these cells. The mitotic serine/threonine kinase, Polo-like kinase-1 (Plk1), is known to phosphorylate and activate a number of mitotic targets, including Cdc2/Cyclin B1, and to promote cell division. The mammalian Plk family are all differentially regulated during the development of rat cardiac myocytes, with Plk1 showing the most dramatic decrease in both mRNA, protein and activity in the adult. We determined the potential of Plk1 to induce cell cycle progression and division in cultured rat cardiac myocytes. A persistent and progressive loss of Plk1 expression was observed during myocyte development that correlated with the withdrawal of adult rat cardiac myocytes from the cell cycle. Interestingly, when Plk1 was over-expressed in cardiac myocytes by adenovirus infection, it was not able to promote cell cycle progression, as determined by cell number and percent binucleation. We conclude that, in contrast to Cdc2/Cyclin B1 over-expression, the forced expression of Plk1 in adult cardiac myocytes is not sufficient to induce cell division and myocardial repair.


  • Effect of acyl chain length on transfection efficiency and toxicity of polyethylenimine

    by Latha Aravindan, Katrina A. Bicknell, Gavin Brooks, Vitaliy V. Khutoryanskiy, Adrian C. Williams


  • Lys-gamma3-MSH: A global regulator of hormone sensitive lipase activity?

    by Katrina A. Bicknell, Stephen C. Harmer, Stephanie Yiangson, Wendy Lockwood, Andrew B. Bicknell


  • Open Access

    The use of proteomics to identify novel therapeutic targets for the treatment of disease

    by Fleur L. Moseley, Katrina A Bicknell, Michael S. Marber, Gavin Brooks

    The completion of the Human Genome Project has revealed a multitude of potential avenues for the identification of therapeutic targets. Extensive sequence information enables the identification of novel genes but does not facilitate a thorough understanding of how changes in gene expression control the molecular mechanisms underlying the development and regulation of a cell or the progression of disease. Proteomics encompasses the study of proteins expressed by a population of cells, and evaluates changes in protein expression, post-translational modifications, protein interactions, protein structure and splice variants, all of which are imperative for a complete understanding of protein function within the cell. From the outset, proteomics has been used to compare the protein profiles of cells in healthy and diseased states and as such can be used to identify proteins associated with disease development and progression. These candidate proteins might provide novel targets for new therapeutic agents or aid the development of assays for disease biomarkers. This review provides an overview of the current proteomic techniques available and focuses on their application in the search for novel therapeutic targets for the treatment of disease.